Request Trial
16 April 2013Americas

Myriad: the oral arguments

On Monday, April 15, the US Supreme Court heard oral arguments on whether genetic material is patent eligible subject matter and in particular, whether Utah-based Myriad Genetics’ patents covering isolated human genes linked to breast and ovarian cancer are valid and enforceable.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit tosses $59m trade secrets judgment against EOFlow
29 May 2026   A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.
Americas
AI, anxiety, and antibodies: The issues dominating life sciences
26 May 2026   Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.
Americas
How should in-house teams adopt AI? ‘Carefully’, says secrets expert
26 May 2026   Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

Kirkland & Ellis adds leading barrister in London
Federal Circuit tosses $59m trade secrets judgment against EOFlow
Neal Gerber Eisenberg expands in Chicago with new litigator
European court backs AstraZeneca unit in blood cancer combo dispute
Takeda’s China IP head: What pharma is still getting wrong
Boehringer Ingelheim adds ex-Teva executive to patent team
AI, anxiety, and antibodies: The issues dominating life sciences
UPC judge: ‘Expectations of you as a woman are the challenge’